(Q42225934)

English

Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis

scientific article published on March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Ming-Chao Tsai

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hsien-Chung Yu

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Chao-Hung Hung

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Chuan-Mo Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ming-Tzung Lin

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Po-Lin Tseng

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Kuo-Chin Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Yi-Hao Yen

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Chien-Hung Chen

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Tsung-Hui Hu

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

568-575

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Epidemiology and natural history of hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Management and prevention of drug resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Renal failure and cirrhosis: a systematic review of mortality and prognosis

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Antiretroviral therapy with tenofovir is associated with mild renal dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12436

21 January 2018

Identifiers

10.1111/JGH.12436

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42225934&oldid=1937077033"